Targeting ligands work by recognizing and binding to specific markers found on cancer cells. These markers, often proteins or antigens, are either exclusive to or significantly more abundant on the surface of cancer cells compared to normal cells. Upon binding, the ligands can either deliver a therapeutic payload directly to the cancer cell or mark the cell for destruction by the immune system.
